« Back
Home /
Mouse PCSK9 Protein (PCS-MM190)

Mouse PCSK9 Protein (PCS-MM190)

Item no.	PCS-MM190-500UG
Manufacturer	KactusBio
Amount	500 ug
Quantity options	100 ug 500 ug
Category	Neuroscience Metabolism Glucose Homeostasis Cholesterol & Lipid Metabolism Molecular Targets for Neuroscience Peptides & Proteins Recombinant Proteins Obesity Lipoprotein Receptors & Associated Proteins
Type	Proteins Recombinant
Format	Lyophilized
Specific against	Mouse (Murine, Mus musculus)
Host	HEK293
Conjugate/Tag	HIS
Purity	> 95% as determined by Bis-Tris PAGE;> 95% as determined by HPLC
Formula	Supplied as 0.22μm filtered solution in 20mM Tris, 150mM NaCL, 200mM L-Aginine (pH 8.2).
Sequence	Gln35-Gln694
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	PC9,PCSK9,FH3,HCHOLA3,LDLCQ1,NARC-1
Shipping Condition	Room temperature
Available
Manufacturer - Type	Recombinant Protein
Manufacturer - Targets	PCSK9
Manufacturer - Conjugate / Tag	C-His
Shipping Temperature	Shipped at ambient temperature.
Storage Conditions	-20 to -80°C for 12 months as supplied from date of receipt.；-80°C for 3 months after reconstitution.；Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Molecular Weight	Due to autocatalytic cleavage, the protein release the pro-form (59 kDa) and mature form (14 kDa). Due to glycosylation, the protein migrates to 65-68 kDa (pro-form) and 15kDa (mature form) based on Bis-Tris PAGE result.
Description	Recombinant Mouse PCSK9 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gln35-Gln694.
Background	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.
Endotoxin	Less than 1 EU per μg by the LAL method.
Formulation	Lyophilized from 0.22μm filtered solution in 20mM Tris, 150mM NaCL, 200mM L-Aginine (pH 8.2). Normally 8% mannitol is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in distilled water. It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1mg/ml for 500μg or 1mg lyophilized powder. Do not mix by vortex or vigorous shaking.
Biotinylated	no

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

PCS-MM190-500UG-datasheet.pdf

PCS-MM190-500UG-safety-datasheet.pdf